Prilenia

“Shaping our Future Together, we are the Change!” is the rallying cry as the @EHA 5th Biannual Conference in Bucharest starts today. Prilenia and Ferrer are united with the #Huntingtonsdisease community, finding strength together to advance therapy, as we prepare for next year’s upcoming confirmatory trial of #pridopidine in early-stage HD. Excited to meet with you all in Romania.

“The published data represents the first Phase 3 HD trial to deliver consistent and meaningful benefits on progression across multiple clinical domains of HD such as function, cognition and motor performance, while also confirming pridopidine’s favorable safety and tolerability profile. Upcoming studies can now refine patient selection and account for the impact of ADM exposure, which obscured the true drug-related benefits. Appropriate stratification and dosage strategies will control for this confounding factor and allow demonstration of pridopidine’s positive treatment effects on clinical progression of symptoms. I would like to express my gratitude for the continued commitment of everyone working to support the next data-driven steps to making this well-tolerated and easily administered treatment option available to HD patients,” said leading HD clinician and researcher Ralf Reilmann, MD, FAAN, Founding Director, George Huntington Institute and lead author, following the recent #NatureMedicine publication of #pridopidine data in #Huntingtonsdisease: That upcoming study is coming soon! Prilenia and Ferrer plan to start a confirmatory study with pridopidine in HD next year! Read more here: https://lnkd.in/dzTVMniy

Fantastic way to drive your important work forward!

“We have no options to help slow down our decline. Nothing to help people feed themselves a little longer, button a shirt a little longer, walk a little longer, or maybe even dance a little longer. Treatment options are needed now that can enable maintenance of independence for as long as possible. These results provide hope that there are therapies that can go further than just symptom control, and hope that we can take a step forward toward availability of a disease-modifying treatment able to slow down the inexorable march of this dreadful disease.” Dina de Sousa, board member at European Huntington Association, on the need for options for #Huntingtonsdisease patients. Prilenia and Ferrer are working hard on meeting that need and have plans in place to start a confirmatory study with #pridopidine in HD next year. Nature Medicine publishes pridopidine Phase 3 data: https://lnkd.in/dmt8gFfa

“We have no options to help slow down our decline. Nothing to help people feed themselves a little longer, button a shirt a little longer, walk a little longer, or maybe even dance a little longer. Treatment options are needed now that can enable maintenance of independence for as long as possible. These results provide hope that there are therapies that can go further than just symptom control, and hope that we can take a step forward toward availability of a disease-modifying treatment able to slow down the inexorable march of this dreadful disease.” Dina de Sousa, board member at European Huntington Association, on the need for options for #Huntingtonsdisease patients. Prilenia and Ferrer are working hard on meeting that need and have plans in place to start a confirmatory study with #pridopidine in HD next year. Nature Medicine publishes pridopidine Phase 3 data: https://lnkd.in/dmt8gFfa

Prilenia and Ferrer today announced publication, in the journal #NatureMedicine, a manuscript entitled "Pridopidine in Early-Stage Manifest Huntington’s Disease: A Phase 3 Trial". The publication describes data showing that treatment with pridopidine slowed clinical progression and maintained function, cognition, and motor performance in a pre-defined subgroup of early-stage #Huntingtonsdisease (HD) patients who were not taking antidopaminergic medicines (ADMs). Pridopidine demonstrated clinically meaningful improvement from baseline for one year, and slowing of decline thereafter, as measured by cUHDRS, throughout the study, with change vs placebo of 0.46, 0.45, 0.41 and 0.27 at 26, 39, 52 and 65 weeks (the end of the double-blind trial). An annual reduction in cUHDRS of 0.1–0.3 points is associated with a clinically meaningful benefit in HD. Pridopidine delivered a consistent pattern of meaningful benefits across multiple clinical domains of HD, while also confirming pridopidine’s favorable safety and tolerability profile. ADMs may cause side effects that cannot be distinguished from HD progression and can negatively impact clinical outcome measures and confound treatment-related effects in a clinical trial. A planned confirmatory study in early HD patients, designed to confirm pridopidine’s effects and support global regulatory approval pathway discussions, is expected to start next year. Read Prilenia’s PR: https://lnkd.in/dzTVMniy European Huntington Association

An inspirational Founder…an inspiring cause…

✨ Building Bridges: EAN endorses EHA Conference 2025✨ We are delighted to announce that the European Huntington Association Conference 2025 has received endorsement from the European Academy of Neurology (EAN). This recognition strengthens the visibility of Huntington’s disease in Neurology and highlights the importance of bringing together families impacted by HD, clinicians and researchers to work towards better care and hope for the future. We are very proud of this endorsement and look forward to welcoming you to the conference in September! 🔗 Register here: https://lnkd.in/e3Kb5RA5 📌 Please note that this endorsement does not imply CME/CPD accreditation or financial support. #EHA #HuntingtonDisease #EuropeanAcademyofNeurology

Disappointed but committed, alongside our partner Ferrer, to providing new much-needed options for patients. We are exploring all options for next steps and our plans for registrational studies in #Huntingtonsdisease and #ALS continue. PR on the CHMP recommendation to refuse the marketing authorization of pridopidine: https://lnkd.in/dkkjJBZ2